Methods
Daily intake of 12 SQ-HDM SLIT-tablet was investigated in the
prospective, multi-center, observational study. It comprised 4
consultations in 1 year. Data on safety, tolerability, treatment
satisfaction, symptomatic medication, compliance, and clinical
effectiveness (Control of Allergic Rhinitis and Asthma Test; CARAT) were
collected. Descriptive and longitudinal regression data analysis was
performed.